

Rec'd PCT/PTC 19 DEC 2005

#5

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88025

Julia CIANCI, et al.

Appln. No.: 10/536,504

Group Art Unit: Unknown

Confirmation No.: 6545

Examiner: Unknown

Filed: May 25, 2005

For: NOVEL CHEMICAL COMPOUNDS AND THEIR USE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/536,504

filing a request for continued examination (RCE) under § 1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 19, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)**Complete if Known*

Application Number	10/536,504
Confirmation Number	6545
Filing Date	May 25, 2005
First Named Inventor	Julia CIANCI
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q88025

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		George He, et al., "Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802", Clin. Pharmacokinet., Dec. 1999, 37 (6), pp. 471-484	
		Hansch, et al., "Hydrophobicity and Central Nervous System Agents: on the Principle of Minimal Hydrophobicity in Drug Design", J. Pharm. Sci., Vol. 76, No. 9, September 1987	
		J. Driscoll, et al., "Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2'-β-Fluoro-2',3'-dideoxyinosine", J. Med. Chem. 1996, 39, 1619-1625	
		Y. Shechter, et al., N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl] ₃ -gentamicin C ₁ Is a Long-Acting Prodrug Derivative" J. Med. Chem. 2002, 45, 4264-4270	
		H. Suzuki, et al., "Improvement of the Bitter Taste of Amino Acids through the Transpeptidation Reaction of Bacterial γ-Glutamyltranspeptidase", J. Agric. Food Chem. 2002, 50, 313-318	
		TA Connors, et al., "Prodrugs in cancer chemotherapy", Stem Cells, Vol. 13, 501-511 (1995)	
		W.M.A. Niessen, "Analysis of antibiotics by liquid chromatography-mass spectrometry", Journal Chromatography A, 812 (1998) 53-75	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.